Gastrointestinal Therapeutics Market Report by Type (Branded, Generic), Route of Administration (Oral, Intravenous, and Others), Application (Ulcerative Colitis, Crohn's Disease, GERD, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmac

Gastrointestinal Therapeutics Market Report by Type (Branded, Generic), Route of Administration (Oral, Intravenous, and Others), Application (Ulcerative Colitis, Crohn's Disease, GERD, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032

The global gastrointestinal therapeutics market size reached US$ 46.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 69.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.

Gastrointestinal (GI) syndrome refers to a medical ailment that affects the functioning of organs in the digestive tract. It impacts the stomach, pancreas, small and large intestines, gall bladder and liver and is usually characterized by indigestion, heartburn, constipation and bloating. Some of the commonly used GI therapeutics include prescription and over-the-counter (OTC) drugs, such as antacids, laxatives, antidiarrheal agents, antiemetics, antiulcer agents, and endoscopic and radiological procedures and hematological tests. These therapeutics assist in the detection of the disorder and absorbing nutrients from the food to improve digestion, regulate water flow in the GI system and minimize gastric acidity.

The increasing prevalence of GI diseases, such as inflammatory bowel disease (IBD) and ulcerative colitis, is one of the key factors driving the growth of the market. Due to changing lifestyle patterns and unhealthy dietary habits, there is an increased probability of disease recurrence among patients across the globe. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Various technological advancements, such as the development of innovative biosimilars and cellular therapies for the treatment of the disorder, are acting as other growth-inducing factors. These biologics are administered through intravenous and subcutaneous injections and are personalized for targeted treatments. Other factors, including rising health consciousness among the masses, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, especially in developing economies, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global gastrointestinal therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, route of administration, application and distribution channel.

Breakup by Type:

• Branded
• Generic

Breakup by Route of Administration:

• Oral
• ntravenous
• Others

Breakup by Application:

• Ulcerative Colitis
• Crohn's Disease
• GERD
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.

Key Questions Answered in This Report:

• How has the global gastrointestinal therapeutics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global gastrointestinal therapeutics market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global gastrointestinal therapeutics market and who are the key players?
• What is the degree of competition in the industry?